The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a recall for Dove Beauty Cream Bar Soap (100g) due to the presence of a harmful chemical impurity. The announcement was made via a statement on the agency’s X (formerly Twitter) account.
NAFDAC explained that the soap contains Butylphenyl Methylpropional, also known as Lilial, a chemical banned in cosmetics because of its potential health risks. The substance is linked to reproductive harm and could negatively affect the health of unborn children. Additionally, it has been associated with skin sensitization, which may lead to allergic reactions in some users.
The statement clarified, “The National Agency for Food and Drug Administration and Control (NAFDAC) is informing the public about the recall of Dove Beauty Cream Bar Soap (100g) with batch number 81832M 08, produced in Germany, due to a chemical impurity. This product violates the Cosmetic Products Regulation as it contains Butylphenyl Methylpropional (BMHCA), a banned substance in the European Union due to its reproductive risks and potential to cause skin sensitization.”
The recall is not limited to Dove soap alone. Other Dove products have also been recalled or banned in various countries due to the presence of BMHCA. These include Dove Derma Spa Goodness, Men Care, Men Care+ Sensitive Shield, Natural Touch, and others such as Go Fresh Revitalize Nourishing Shower Gel, Invisible Dry Antiperspirant Spray, and Caring Hand Wash.
NAFDAC stated that the recalled soaps are not listed in its database and reminded the public that the importation of soap is prohibited in Nigeria, as it is on the country’s restricted and import prohibition list. The agency warned consumers, importers, distributors, and retailers to remain vigilant within the supply chain to prevent the sale, distribution, or use of the affected products.
“Members of the public who are in possession of this product are advised to discontinue its use or sale and submit any remaining stock to the nearest NAFDAC office,” the statement continued.
NAFDAC also urged healthcare professionals and consumers to report any adverse effects from using regulated products to the agency. Reports can be made via email at pharmacovigilance@nafdac.gov.ng, through the agency’s e-reporting platforms on its website, or by using the Med-Safety app, available for download on Android and iOS devices.
For more information, join our WhatsApp channel: https://whatsapp.com/channel/0029VabITrvEAKW7DSkTfP0.